课题基金 / 基金详情

21ENGBIO Controllable DNA polycatenanes of infinite length for intelligent biomaterials

21ENGBIO Controllable DNA polycatenanes of infinite length for intelligent biomaterials
21ENGBIO 用于智能生物材料的无限长度可控 DNA 聚链烷
批准号:
BB/W01338X/1
负责人:
Susan Rosser
金额:
$12.85万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2022
资助国家:
英国
项目状态:
已结题
起止时间:
2022 至 --

项目摘要

项目成果

Susan Rosser的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DNA is an ideal substrate from which to construct new materials for medical applications because it is sustainable, biodegradable, biocompatible, non-toxic, and highly programmable. DNA hydrogels have state-of-the-art applications in regenerative therapy (like stimulating new tissue growth from stem cells) and biologics delivery (like controlled, sustained release of insulin). They are squishy, gel-like materials made of water and web-like structures of DNA, and they can obtain unique properties when combined with nanomaterials. The disadvantages of current DNA hydrogels are in how their web-like structures of DNA are held together. Many rely on the ability of compatible DNA strands to stick together but this stickiness is susceptible changes in environmental conditions such as an increase in temperature which causes the structures to unravel. Adding small molecules to reinforce the DNA structures through cross-linking increases the manufacturing time and cost. Here, we will synthesise never-before-made DNA-based materials from polycatenanes. Polycatenanes are polymers in which molecular rings are mechanically linked together akin to the links of a chain. We have devised a strategy to make DNA polycatenanes of infinite and controllable lengths using enzymes to connect rings of DNA. In addition to enabling assembly 1D DNA chains, our strategy will enable construction of 2D and 3D DNA structures that require no cross-linking small molecules and will not unravel upon changes in environmental conditions. This work aims to seed development of a new family of structurally unique DNA-based biomaterials for programmable biologics delivery and patient-specific regenerative therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineered Genetic Control Systems for Advanced Therapeutics
  • 批准号:
    BB/Y008545/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $1575.86万
  • 财政年份:
    2024
  • 负责人:
    Susan Rosser
  • 依托单位:
21EBTA Engineering Biology for Cell and Gene Therapy Applications
  • 批准号:
    BB/W014610/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $193.46万
  • 财政年份:
    2022
  • 负责人:
    Susan Rosser
  • 依托单位:
Optimisation of CHO for Biotherapeutic Manufacture
  • 批准号:
    EP/V038095/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $472.6万
  • 财政年份:
    2021
  • 负责人:
    Susan Rosser
  • 依托单位:
A Novel Single Subunit RNA Polymerases for Commercial RNA Manufacturing
  • 批准号:
    BB/T017236/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $25.78万
  • 财政年份:
    2020
  • 负责人:
    Susan Rosser
  • 依托单位:
海外基金